Breaking Industry Barriers: Discovering BAY2927088, Novel Inhibitor of ERBB2 Mutants in NSCLC
Time: 11:30 am
day: Conference Day One
Details:
- Unpacking challenges of mutant-selective kinase inhibition: targeting EGFR/ERBB2 exon 20 insertion mutants
- Evaluating biochemical and cellular approaches to developing inhibitors for untargetable mutant TYK
- Revealing clinical data on selectivity for ERBB2 exon 20 insertion mutants in NSCLC
